Global market access capabilities
Unlock your product potential with a global market access partner:
- Engage - early with stakeholders
- Monitor - global and local Health Technology (HTA) landscape
- Design - strong evidence and submission packages
- Leverage - opportunities for HTA interactions & generate real-world evidence
- Communicate - your product's value
- Apply - critical health economics and outcomes research information
Our global biopharma consulting capabilities
Health economics & outcomes research
Market access consulting
When launching products outside the U.S., Xcenda provides deep understanding of the environment, competition, and considerations for market access across Europe and HTA countries. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials.
With strategic global data partnerships in the US, Germany, the UK, the Netherlands, France, Sweden, Canada, Japan, and China, we support our clients' global strategies along the entire product lifecycle.
Our databases are sourced from administrative claims, electronic medical records, or disease registries, and capture patient-level health information and outcomes for healthcare services performed in various care settings.
In the News
AmerisourceBergen completes acquisition of PharmaLex in January 2023
Ask local experts from markets worldwide
Global market access network
Our global market access and consulting insights
New pan-EU HTA: How can biopharma navigate the joint clinical assessment?
The new European Union (EU) Health Technology Assessment (HTA) regulation was enacted in January 2022 with the primary objective of streamlining the clinical assessment process for EU member states' HTA bodies. Biopharma companies need to be aware of the clinical development and market access processes in this uncharted environment. Enter your information below to read about how biopharma can approach their planning more successfully.
Three questions to ask about your market access partner
The new EU regulation on health technology assessment: Major change or minor adjustment?
Taking into account different comparator products, HTA methodologies and policy questions in individual member states and the need for submission of country-specific economic evidence, we consider what the new 2022 European Union (EU) health technology assessment (HTA) regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.
Each investment we make is focused on connecting healthcare stakeholders to accelerate healthier futures. Our unrivaled expertise powers us in our vision to help you fully realize your product’s power—through the patients it reaches and the strategic outcomes it delivers. Learn more about our end to end suite of commercialization solutions for biopharma companies.
Let's work together to envision new paths to healthier futures around the world.